Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dema A. Ali"'
Publikováno v:
AIMS Molecular Science, Vol 8, Iss 1, Pp 60-75 (2021)
Alkaptonuria (AKU) is a rare metabolic disease which is inherited as an autosomal recessive trait. It is characterized by the accumulation of homogentisic acid over time in various tissues of the body particularly connective tissues. This genetic dis
Externí odkaz:
https://doaj.org/article/1702b8d5702145bc87b2f5dba370f1ee
Autor:
Ahmed Al-jedai, Hadeel Alkofide, Lujaine Almohimeed, Lama Alsalim, Alya Alruwaili, Dema A. Alissa, Hajer Almudaiheem
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 12, Pp 101851- (2023)
Background: The Saudi Food and Drug Authority (SFDA) classified pregabalin as a controlled substance in 2018; however, whether this policy change has affected pregabalin use is unclear. This study examined the trends in pregabalin prescriptions befor
Externí odkaz:
https://doaj.org/article/ae562f128bd04f819f0709d06d153aeb
Autor:
Ibtisam A. Al Thubaiti, Mona M. AlKhawajah, Norah Al Fugham, Dema A. Alissa, Ahmed H. Al-Jedai, Yaser M. Al Malik, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Bedor A. Al-Omari, Hessa S. AlOtaibi, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, Reem F. Bunyan, Edward J. Cupler, Mohammed Hakami, Hanaa M. Kedah, Seraj Makkawi, Leena H. Saeed, Jameelah A. Saeedi, Eslam Shosha, Mohammed A. Al Jumah
Publikováno v:
Clinical and Translational Neuroscience, Vol 7, Iss 1, p 6 (2023)
This article deals with recommendations on the management of symptoms of MS and on the provision of vaccinations in patients receiving disease-modifying therapies (DMTs). Symptoms of MS, such as fatigue, depression, urinary symptoms, spasticity, impa
Externí odkaz:
https://doaj.org/article/2183e4d78c6e4b98b414b3349982ffa1
Autor:
Yaser M. Al Malik, Ibtisam A. Al Thubaiti, Maha A. AlAmmari, Norah Al Fugham, Eman N. Ali, Dema A. Alissa, Salman A. Aljarallah, Ahmed H. Al-Jedai, Maeed A. AlKathiri, Mona M. AlKhawajah, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Hessa S. Al Otaibi, Ghadah H. AlTowaijri, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, Saeed A. Bohlega, Reem F. Bunyan, Edward J. Cupler, Mohammed Hakami, Abid M. Kareem, Amr M. Khardaly, Seraj Makkawi, Leena H. Saeed, Jameelah A. Saeedi, Eslam Shosha, Mohammad A. Al Jumah
Publikováno v:
Clinical and Translational Neuroscience, Vol 6, Iss 4, p 27 (2022)
For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnos
Externí odkaz:
https://doaj.org/article/2fb7ce205ae64e98a94d6195cedec570